Vilon 20 mg

Vilon 20mg is a synthetic dipeptide bioregulator with the amino acid sequence Lys-Glu (KE / Lysyl-Glutamic Acid), originally derived from thymus tissue extracts and developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. With a molecular weight of approximately 275 Da and molecular formula C₁₁H₂₁N₃O₅, Vilon is the smallest bioactive compound in the Khavinson thymic bioregulator cluster — alongside Thymalin and Thymogen — and holds a unique position as the most minimal peptide sequence known to demonstrate significant tissue-specific immunomodulatory activity.

Research into Vilon centers on its proposed epigenetic mechanism of chromatin decondensation in thymic and immune cell populations, restoring gene expression programs governing T-lymphocyte proliferation, differentiation, and immune surveillance that are progressively silenced during thymic involution and immunosenescence. Published preclinical studies have documented Vilon’s effects on thymocyte proliferative activity following radiation exposure — increasing thymic proliferating cell nuclear antigen (PCNA)-positive nuclei from 26% to 37% — thymic cortical layer expansion, apoptosis inhibition in immune cells, and reduced incidence of pulmonary adenoma and mammary adenocarcinoma cells in laboratory models. Long-term treatment data from Khavinson’s group reports mean lifespan increases of 20–40% in rodent models.

Beyond Health Lab supplies Vilon 20mg as a research-grade lyophilized compound, HPLC-verified for 99% purity, shipped within 24 hours from Mexico.

For research use only. Not intended for human or animal consumption.

FAQ:

What is Vilon and how does it differ from Thymogen and Crystagen in the Khavinson thymic system?
Vilon (Lys-Glu / KE) is a synthetic dipeptide derived from thymus tissue, classified alongside Thymogen (Glu-Trp) and Crystagen (EDP) in the Khavinson thymic bioregulator cluster. All three target immune cell populations but through distinct mechanisms and with different tissue breadths. Vilon is the smallest of the three (275 Da) and is primarily studied for its direct epigenetic effects on thymocyte proliferation and thymic architecture — making it the most targeted tool for thymus-specific chromatin remodeling research. Crystagen has the broadest immune profile across T-cells, B-cells, spleen, and bone marrow; Thymogen focuses on T-cell differentiation pathways.

What are the most significant preclinical findings associated with Vilon research?
Published research documents a documented increase in thymic PCNA-positive nuclei from 26% to 37% in radiation-exposed models, indicating restored thymocyte proliferative activity. Additional findings include thymic cortical layer expansion through thymocyte proliferation, apoptosis inhibition in immune cells (Khavinson and Kvetnoii, Bull Exp Biol Med 2000), reduced incidence of pulmonary adenoma and mammary adenocarcinoma cells in laboratory models, and mean lifespan increases of 20–40% in long-term rodent studies. Key published reference: Sevostianova et al. Bull Exp Biol Med (2013) on immunomodulating effects in human and animal thymus cell culture.

What is the significance of Vilon’s minimal molecular size in immune research?
At 275 Da and just two amino acids, Vilon is the simplest peptide sequence known to exhibit significant thymic bioregulatory activity — making it scientifically significant as a proof-of-concept that minimal peptide sequences can encode tissue-specific gene regulatory information. This minimal architecture also provides analytical advantages: straightforward quantification by LC-MS/MS in complex biological matrices including plasma and tissue homogenate, facilitating pharmacokinetic studies that are difficult with larger bioregulator peptides.

How should Vilon 20mg be stored?
Store lyophilized Vilon at 2–8°C away from light and moisture. Once reconstituted with bacteriostatic water, keep refrigerated and use within 28 days for optimal stability and research-grade performance.